Featured Research

from universities, journals, and other organizations

Anti-Angiogenic Drug Much More Effective When Immune System Primed Against Cancer

Date:
June 13, 2000
Source:
University Of Pittsburgh Medical Center
Summary:
Agents that starve tumors by cutting off their blood supply have come to the forefront in experimental cancer therapies within recent years. Promising though they are, these anti-angiogenic drugs are no magic bullet. When treatment with them is discontinued in experimental models, tumors rebound because small pockets of viable cancer cells remain. Now, University of Pittsburgh scientists have shown that triggering an anti-tumor immune response significantly potentiates the effects of the anti-angiogenic drug endostatin in animal models, leading to permanent and complete regression in half of treated animals.

PITTSBURGH, June 9 - Agents that starve tumors by cutting off their blood supply have come to the forefront in experimental cancer therapies within recent years. Promising though they are, these anti-angiogenic drugs are no magic bullet. When treatment with them is discontinued in experimental models, tumors rebound because small pockets of viable cancer cells remain. Now, University of Pittsburgh scientists have shown that triggering an anti-tumor immune response significantly potentiates the effects of the anti-angiogenic drug endostatin in animal models, leading to permanent and complete regression in half of treated animals. These results are being presented Sunday, June 11, at the Era of Hope/Department of Defense breast cancer meeting in Atlanta.

"We have the first data suggesting that anti-tumor immunotherapy combined with vascular inhibition is a promising treatment strategy for cancer," said Eli Gorelik, Ph.D., professor of pathology at the University of Pittsburgh School of Medicine and a member of the University of Pittsburgh Cancer Institute (UPCI). "Increasing anti-tumor immunity and combining this approach with anti-angiogenic drugs could provide a highly effective cancer therapy."

This combined therapy uses endostatin to prevent blood flow to the tumor, leading to tumor starvation, and then uses the body's immune system to kill the remaining cancer cells.

In their research, Dr. Gorelik and his colleagues studied endostatin in two groups of mice, one group with lung cancer cells that fail to stimulate the immune system (3LL cells) and in another group with so-called immunogenic lung tumor cells (3LL-C75 cells). Because they carry special markers on their surface, immunogenic cells stimulate the body's own immune cells to recognize and destroy them.

The investigators found that endostatin inhibited tumor growth in 3LL-bearing animals. However, an 18-day course of endostatin eradicated cancers in 40 percent of animals bearing 3LL-C75 tumors, suggesting that tumor immunity is essential for complete eradication of tumor cells remaining after endostatin therapy. To increase the therapeutic efficacy of endostatin against the non-immunogenic 3LL cells, mice either were vaccinated with 3LL-C75 cells or were treated with interleukin-12. These 3LL-bearing animals were then treated with endostatin. Half of the animals became well, with complete and permanent regression of tumors. No regression of 3LL tumors was observed in mice treated separately with either endostatin alone or by tumor vaccination.

More recently, the UPCI investigators have found that endostatin significantly inhibits growth of breast cancer in mice. Future studies are underway to determine whether endostatin together with anti-tumor immunity yields sustained, complete breast tumor regression. The long-term goal is to develop a clinical protocol for breast cancer incorporating both strategies. The research is supported by a Department of Defense research grant.


Story Source:

The above story is based on materials provided by University Of Pittsburgh Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pittsburgh Medical Center. "Anti-Angiogenic Drug Much More Effective When Immune System Primed Against Cancer." ScienceDaily. ScienceDaily, 13 June 2000. <www.sciencedaily.com/releases/2000/06/000612084128.htm>.
University Of Pittsburgh Medical Center. (2000, June 13). Anti-Angiogenic Drug Much More Effective When Immune System Primed Against Cancer. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2000/06/000612084128.htm
University Of Pittsburgh Medical Center. "Anti-Angiogenic Drug Much More Effective When Immune System Primed Against Cancer." ScienceDaily. www.sciencedaily.com/releases/2000/06/000612084128.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins